Skip to Content
  • Previous Rank
    305
  • Revenues ($M)
    $11,229
  • Revenue Percent Change
    21.3%
  • Profits ($M)
    $1,999.2
  • Profits Percent Change
    24.8%
  • Assets ($M)
    $28,086
  • Employees
    7,132
  • Market Value — as of March 31, 2017 ($M)
    $96,802

The biopharmaceutical company is the maker of Thalomid and various other drugs that treat multimple myeloma, inflammatory diseases, and various forms of cancer.

Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Company Info

CEO
Mark J. Alles
CEO Title
Chief Executive Officer & Director
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
Summit, NJ
Websitehttp://www.celgene.com
Years on Fortune 500 List6
Employees7,132

Celgene Rank History

placeholder

Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$11,22921.3%
Profits ($M)$1,999.224.8%
Assets ($M)$28,086-
Total Stockholder Equity ($M)$6,599-
Market Value — as of March 31, 2017 ($M)$96,802-

Profit Ratios

Profit as % of Revenues17.8%
Profits as % of Assets7.1%
Profits as % of Stockholder Equity30.3%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)2.49
EPS % Change (from 2015)28.4%
EPS % Change (5 year annual rate)11.8%
EPS % Change (10 year annual rate)39.4%

Total Return

Total Return to Investors (2016)-3.3%
Total Return to Investors (5 year, annualized)27.9%
Total Return to Investors (10 year, annualized)14.9%